Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Highlights of Merck’s Q4 2023 financial results
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp fall in adjusted earnings for the fourth quarter of 2023, despite a modest increase in revenues.
Fourth-quarter worldwide sales increased 6% year-over-year to $14.6 billion, mainly reflecting the sustained growth across oncology and vaccines.
The company reported a net loss of $1.23 billion or $0.48 per share for the December quarter, compared to a profit of $3.02 billion or $1.18 per share in the prior-year period. On an adjusted basis, it was earnings of $0.03 per share in Q4, down 98% from the fourth quarter of 2022.
“As we move forward, I’m confident that our strong momentum will continue, underpinned by the unwavering dedication of our talented global team,” said Merck’s CEO Robert Davis.
Prior Performance
Most Popular
CL Earnings: Key quarterly highlights from Colgate-Palmolive’s Q2 2024 financial results
Colgate-Palmolive Company (NYSE: CL) reported its second quarter 2024 earnings results today. Net sales increased 4.9% year-over-year to $5 billion. Organic sales increased 9%. Net income attributable to Colgate-Palmolive Company was $731
Key takeaways from Visa’s Q3 2024 earnings report
Credit card behemoth Visa, Inc. (NYSE: V) this week reported mixed results for the June quarter, with earnings matching expectations and sales slightly missing the view. Both numbers grew in
Southwest Airlines (LUV): A look at the airline’s performance in Q2 2024
Shares of Southwest Airlines Co. (NYSE: LUV) were up over 6% on Thursday after the company beat earnings estimates for the second quarter of 2024. The stock has gained 4%
